B.K. Mody Government Pharmacy College

ABOUT AUTHOR:
Vivek P. Chavda
Department of Pharmaceutics, B.K. Mody Government Pharmacy College,
Rajkot – 360003, Gujarat (India)
vivek7chavda@gmail.com

ABSTRACT
Cancer is one of most cogent culprit for causes of mortality in society. Chemotherapy, radiation therapy and surgery are the elements which are endorsed to combat it. Nowadays antibodies are also gaining much attention in cancer treatment. Antibodies are found to be important and most promising and target specific therapeutic agents for cancer due to their epitope specific interaction. Many clinically useful antibodies can manipulate tumour-related signaling. In addition, antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses. Antibody-drug conjugates prove to be more promising in the treatment.

About Author:
Vivek P. Chavda
Department of Pharmaceutics, B.K. Mody Government Pharmacy College,
Rajkot – 360003, Gujarat (India)
vivek7chavda@gmail.com

Abstract
This technology has just revolutionized the cancer treatment. It is clearly a tool of exceptional value in the functionalization of genes and their validation as potential targets for cancer chemotherapy. Furthermore, a rapidly expanding repertoire of antisense therapy based on the use of antisense oligonucleotides (AONs), small interfering RNAs (siRNAs), micro RNAs (miRNAs), ribozymes and other antisense compounds is being developed to block over expression of key oncogenes and other tumor promoting genes in the treatment of different tumors and many of these nucleic acid-based drugs have demonstrated impressive preclinical and clinical responses.This review highlight some of the cardinal feature of this technology.